Gufic Biosciences (509079) investor relations material

Executive summary

• Indore plant is fully operational, with new depot and microsphere suites nearing completion and expansion into lipid-based antifungals underway.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and the incorporation of a new subsidiary in the Philippines focused on marketing, sales, and distribution, with an investment of up to USD 250,000 and 99.99% ownership.

• Focus this year is on deepening hospital network coverage, expanding own manufactured brands, and launching the widest product pipeline to date.

• International business model shifted from distributor-led to IP-led, with new teams in Mexico, Africa, and Southeast Asia to drive front-end presence.

• Strategic tie-up with Clinton Health Access Initiative for liposomal amphotericin B to access over 100 markets.

Financial highlights

• Q1 FY27 consolidated revenue rose to ₹26,081.80 lakhs from ₹22,691.15 lakhs in Q1 FY26; standalone revenue was ₹260.8 crore, up 15% year-over-year and 3% sequentially.

• EBITDA increased to ₹47.2 crore (margin 18.09%) from ₹33.2 crore (14.6%) YoY.

• Profit after tax grew to ₹22.46 crore (PAT margin 8.61%) from ₹12.1 crore (5.3%) YoY; consolidated net profit was ₹2,231.28 lakhs.

• Profit before tax reached ₹30.1 crore, up from ₹16.3 crore YoY.

• Basic and diluted EPS for Q1 FY27 stood at ₹2.22, up from ₹1.30 in Q1 FY26.

Outlook and guidance

• Expecting 15%-20% year-over-year revenue growth, with margin improvement as capacity utilization and product mix evolve.

• Indore facility utilization projected to reach 40%-45% by year-end, with further margin expansion anticipated post-EU certification.

• Expansion into the Philippines is expected to facilitate business growth and international presence.

• Peak revenue potential with current infrastructure estimated at ₹1,600-2,000 crore, depending on product mix.

• Targeting 5–10% market share in identified geographies over 3–5 years.